Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain OPNT message board posts where the ticker symbol OPNT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest OPNT SEC Filings

Filings Format Description Filing Date File/Film Number
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000932471-13-002597 (34 Act)  Size: 46 KB
2013-02-11 005-60291
13589481
15-12G  Documents Securities registration termination [Section 12(g)]
Acc-no: 0001193125-12-518791 (34 Act)  Size: 11 KB
2012-12-31 000-30931
121292416
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001144204-12-069989 (34 Act)  Size: 42 KB
2012-12-28 005-60291
121290185
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001144204-12-069987 (34 Act)  Size: 42 KB
2012-12-28 005-60291
121290178
SC 13D/A  Documents [Amend] General statement of acquisition of beneficial ownership
Acc-no: 0001193125-12-510792 (34 Act)  Size: 78 KB
2012-12-21 005-60291
121278392
SC TO-T/A  Documents [Amend] Tender offer statement by Third Party
Acc-no: 0001193125-12-510792 (34 Act)  Size: 78 KB
2012-12-21 005-60291
121278391
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-12-058920 Size: 7 KB
2012-12-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-12-058763 Size: 15 KB
2012-12-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-12-058762 Size: 7 KB
2012-12-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-12-058761 Size: 8 KB
2012-12-20
More OPNT SEC Filings


Related news from
Thu, 07 Dec 2017
15:26:32 +0000
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q1, 2018 By the Numbers : December 7, 2017
Categories: Yahoo FinanceGet free summary analysis Opiant Pharmaceuticals, Inc. reports financial results for the quarter ended October 31, 2017. We analyze the earnings along side the following peers of Opiant Pharmaceuticals, Inc. – GW Pharmaceuticals PLC Sponsored ADR and Arena Pharmaceuticals, Inc. (GWPH-US and ARNA-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more <b>(Read more...)</b>
Mon, 04 Dec 2017
21:05:00 +0000
Opiant Pharmaceuticals, Inc. Reports Fiscal First Quarter 2018 Financial Results
SANTA MONICA, Calif., Dec. 04, 2017-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the fiscal ...
Mon, 16 Oct 2017
19:00:00 +0000
OPNT: Looking to Keep Momentum Going into Fiscal 2018
Opiant Pharmaceuticals, Inc. (OPNT) is a specialty pharmaceutical company developing treatments for substance use, eating disorders, and addiction disorders based on the company’s expertise in opioid receptor antagonists. Opiant currently has one FDA approved drug, NARCAN® Nasal Spray, which is marketed by Adapt Pharmaceuticals through an exclusive collaboration. Fiscal 2017 was a transformative year for Opiant, as the company monetized the royalties for NARCAN® Nasal Spray, uplisted to the Nasdaq stock exchange, strengthened the leadership team with the appointment of a new Chief Financial Officer, and announced encouraging Phase 1 data for OPNT002 in Alcohol Use Disorder (AUD).
Fri, 13 Oct 2017
23:17:29 +0000
Is It Time To Buy Opiant Pharmaceuticals Inc (OPNT) Based Off Its PE Ratio?
Opiant Pharmaceuticals Inc (NASDAQ:OPNT) trades with a trailing P/E of 12.4x, which is lower than the industry average of 23.5x. While this makes OPNT appear like a great stock toRead More...
Fri, 13 Oct 2017
11:00:00 +0000
Opiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
SANTA MONICA, Calif, Oct. 13, 2017-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the fiscal ...
Wed, 04 Oct 2017
11:20:00 +0000
Corporate News Blog - Titan Pharma and Opiant Pharma Collaborate to Discover a New Approach for Treatment of Opioid Use Disorder
LONDON, UK / ACCESSWIRE / October 4, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ), following which we have ...
Mon, 02 Oct 2017
11:00:00 +0000
Titan Pharmaceuticals and Opiant Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder Treatment
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) and Opiant Pharmaceuticals, Inc. (OPNT) today announced a collaboration to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The companies will conduct a feasibility assessment of a subcutaneous implant using Titan's proprietary ProNeura™ sustained release technology to administer an opioid antagonist. A product that delivers non-fluctuating, therapeutic levels of an opioid antagonist, continuously for up to 6 months, may be ideally suited for the prevention of opioid relapse and overdose.
Mon, 02 Oct 2017
11:00:00 +0000
Opiant Pharmaceuticals and Titan Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder Treatment
SANTA MONICA, Calif., Oct. 02, 2017-- Opiant Pharmaceuticals, Inc. and Titan Pharmaceuticals, Inc. today announced a collaboration to explore development of a novel approach to the prevention of opioid ...
Mon, 25 Sep 2017
11:00:00 +0000
Opiant Pharmaceuticals, Inc., CEO Roger Crystal, M.D., to Present to President's Commission on Combating Drug Addiction and the Opioid Crisis
SANTA MONICA, Calif., Sept. 25, 2017-- Opiant Pharmaceuticals, Inc.,, today announced that Chief Executive Officer Roger Crystal, M.D., has been invited to testify before the President's Commission on ...
Wed, 20 Sep 2017
16:22:00 +0000
Opiant Up Nearly 30% On Favorable Zacks Report
Opiant Pharmaceuticals jumped nearly 30% yesterday on a favorable report from Zacks, making it the forth largest position in Todd Hagopian's Biotech Fund. Here's what Todd thinks of the news.
Tue, 19 Sep 2017
14:00:00 +0000
OPNT: Estimating When Royalties to NARCAN® Nasal Spray Revert Back to Opiant
On December 15, 2016, Opiant Pharmaceuticals, Inc. (OPNT) announced an agreement with SWK Holdings Corporation whereby SWK acquired the rights to certain royalty and milestone payments related to the sale of NARCAN® Nasal Spray for an initial payment of $13.7 million and the potential for an additional $3.75 million if certain future net sales milestones are met. On August 10, 2017, Opiant announced an additional $3.75 million payment from SWK related to the royalty monetization agreement related to the sale of NARCAN® Nasal Spray signed between Opiant and SWK in December 2016. According to the agreement, the $3.75 million payment was due to Opiant upon Adapt Pharma recording >$25 million in cumulative net sales of NARCAN® Nasal Spray for any two consecutive quarters from Oct. 1, 2016 to Sep. 30, 2017.
Mon, 18 Sep 2017
11:00:00 +0000
Corporate News Blog - Opiant Delivers Update on NARCAN Nasal Spray; Surpasses $25 Million Net Sales in H1 2017
Research Desk Line-up: SeaChange Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Opiant ...
Fri, 15 Sep 2017
11:00:00 +0000
Opiant Pharmaceuticals, Inc. Provides an Update on NARCAN® Nasal Spray
SANTA MONICA, Calif., Sept. 15, 2017-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, today provided an update on NARCAN ® Nasal ...
Tue, 29 Aug 2017
19:00:00 +0000
OPNT: Uplists to NASDAQ
By David Bautz, PhD NASDAQ:OPNT Opiant Uplists to the Nasdaq Stock Exchange On August 28, 2017, Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced its shares of common stock were approved for listing ...
Thu, 10 Aug 2017
17:00:00 +0000
OPNT: Receives Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization
On August 10, 2017, Opiant Pharmaceuticals Inc. (OPNT) announced an additional $3.75 million payment from SWK Holdings Corporation related to the royalty monetization agreement related to the sale of NARCAN® Nasal Spray signed between Opiant and SWK in December 2016. According to the agreement, the $3.75 million payment was due to Opiant upon Adapt Pharma recording >$25 million in cumulative net sales of NARCAN® Nasal Spray for any two consecutive quarters from Oct. 1, 2016 to Sep. 30, 2017. The royalty monetization agreement with SWK stipulates that SWK will receive all royalties on the sale of NARCAN® Nasal Spray up to $26.25 million dollars.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum has meant the difference between mediocre and stellar stock performance, peace of mind about retirement and meeting and making wonderful friends. VF is simply the BEST." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards